FGFR3 and urinary bladder cancer: Most recently, it was shown in a phase 3 study that erdafitinib is superior to chemotherapy in the therapy of advanced or metastatic bladder cancer in patients with unresectable, advanced or metastatic urothelial cancer and select FGFR3/2 receptor alterations (mutations/fusions) (Loriot et al., 2023[29]) According to the TCGA data base, 15.43 % (29 out of 188) bladder cancer cases provided somatic mutations in their tumors (NIH, 2023[34]).